雌激素快速影响大鼠发育期海马NMDA受体活性的机制

为了探讨雌激素对发育期大鼠海马NMDA受体活性的快速影响,对出生后18d的雄性大鼠进行苯甲酸雌二醇皮下注射,1h后用WesternBlot检测海马NMDA受体NR1和NR2B亚基、雌激素β受体、ERK1/2蛋白的表达,以及NR2B和ERK1/2的磷酸化水平;并通过海马内给予雌激素受体拮抗剂ICI182,780和MEK1/2抑制剂U0126预处理,进一步分析苯甲酸雌二醇影响NR2B和ERK1/2磷酸化的作用机制。结果显示,苯甲酸雌二醇不影响NR1、NR2B、ERβ和ERK1/2的表达,但能快速增强NR2B和ERK1/2的磷酸化水平。雌激素受体拮抗剂ICI182,780和MEK1/2抑制剂U0126均能明显抑制苯甲酸雌二醇诱导的NR2B和ERK1/2磷酸化水平的增加。以上结果提示,雌激素可能通过雌激素受体的非基因组机制激活ERK/MAPK信号转导通路,快速诱导NMDA受体NR2B亚基磷酸化,激活NMDA受体。     

雌激素快速激活MAPK途径促进前列腺间质细胞的增殖

为研究雌激素促进前列腺间质细胞增殖的机理,使用雌二醇（E2）或BSA雌二醇（BSA-E2）处理前列腺间质细胞系wpmy-1,用MTT法及细胞计数法检测细胞增殖情况;用实时RT-PCR以及Western印迹方法检测细胞增殖核抗原（PCNA）的表达水平;用抗磷酸化ERK1/2抗体检测细胞内MAPK途径的激活情况.结果显示,2种形式的雌二醇均能促进前列腺间质细胞系wpmy-1的增殖,并且显著上调增殖相关核抗原PCNA的表达水平;2种形式的雌激素均能快速激活wpmy-1细胞内的MAPK信号通路;MAPK途径的特异性抑制剂PD98059能够显著降低雌激素对细胞增殖以及PCNA表达水平的上调作用.结果表明,雌激素能够通过膜受体快速激活前列腺间质细胞中的MAPK信号通路,进而促进前列腺间质细胞的增殖.     

利用GFP表达系统检测雌激素类化合物的研究

根据雌激素类化合物的转录调节原理,构建受雌激素应答元件（ERE）调控的3×ERE EGFP-N1重组报告基因载体,转染雌激素受体阳性的MCF-7乳腺癌细胞,分离出稳定转染的细胞克隆ERE-GFP-MCF7,将不同浓度的雌二醇（E2）及其他化合物加入稳定转染的细胞后检测GFP表达水平的变化。雌二醇（E2）以剂量依赖的方式诱导稳定转染细胞ERE-GFP-MCF7表达GFP,最大效应浓度为1×10－10mol/L ,EC50为1.5×10－11 mol/L;已知的植物雌激素大豆甙元和白藜芦醇同样以剂量依赖的方式诱导GFP的表达,EC50分别为2.4×10－7 mol/L和6.2×10－6 mol/L,而葡萄籽多酚没有明显的雌激素样活性。雌激素拮抗剂他莫西芬以剂量依赖的方式抑制雌二醇诱导GFP的表达,最大抑制浓度为1×10－7 mol/L。利用此细胞模型检测不同化合物诱导的GFP表达强度可快速检测雌激素受体的配体。     

P38 MAPK 信号传导通路与卵巢癌关系的研究进展

丝裂原活化蛋白激酶(mitogen-activated proteinkinases,MAPKs)级联反应是细胞内重要的信号传导系统之一,参与细胞生长、发育、分化和凋亡等一系列生理、病理过程.P38 MAPK信号传导通路是MAPK通路的分支之一,介导了应激、炎性细胞因子、细菌产物等多种刺激引起的细胞反应,对细胞周期调控具有重要作用.但对不同的卵巢癌细胞系,或者不同的刺激,P38通路的作用不完全相同,甚至可能相反,提示对P38通路的功能仍需进一步的研究,他可能是肿瘤治疗的新靶点.本文就P38 MAPK信号传导通路与卵巢癌关系作一综述。     

P38MAPK信号传导通路与卵巢癌关系的研究进展

丝裂原活化蛋白激酶（mitogen-activatedproteinkinases,MAPKs）级联反应是细胞内重要的信号传导系统之一,参与细胞生长、发育、分化和凋亡等一系列生理、病理过程．P38MAPK信号传导通路是MAPK通路的分支之一,介导了应激、炎性细胞因子、细菌产物等多种刺激引起的细胞反应,对细胞周期调控具有重要作用．但对不同的卵巢癌细胞系,或者不同的刺激,P38通路的作用不完全相同,甚至可能相反,提示对P38通路的功能仍需进一步的研究,他可能是肿瘤治疗的新靶点．本文就P38MAPK信号传导通路与卵巢癌关系作一综述。     

ERK1/2在食管鳞状细胞癌中促进细胞增殖、抑制凋亡及其调控机制的研究

探讨ERK1/2在食管鳞状细胞癌(ESCC)中对肿瘤细胞增殖、凋亡的调控及其机制。平板克隆、细胞凋亡和细胞周期实验结果发现ERK1/2 MAPK通路抑制可减弱Eca109细胞克隆形成和增殖,促进细胞凋亡,减慢细胞周期;进一步发现ERK1/2 MAPK通路抑制可以反转由mi R-21过表达诱导的Eca109细胞增殖、凋亡和周期的变化;q RT-PCR和Western-blot免疫印迹结果发现ERK1/2 MAPK信号通路抑制可以下调内源性mi R-21表达和反转外源性mi R-21诱导的ERK1/2 MAPK信号通路活化。实验结果提示ERK1/2 MAPK通路抑制可能通过下调Eca109细胞中mi R-21表达阻碍Eca109细胞增殖、促进细胞凋亡和减慢细胞周期,最终导致ESCC细胞生长抑制。     

瘦素对卵巢癌细胞 SKOV3 增殖及凋亡的影响

目的:探讨瘦素对人卵巢癌SKOV3细胞增殖及凋亡的影响及其作用机制。方法:用不同浓度的瘦素(0、50、100、200 ng/m L)处理人卵巢癌SKOV3细胞48 h后,采用MTT法检细胞的生长;以血清饥饿诱导细胞凋亡,同时给予瘦素刺激,Annexin V/PI双染法检测细胞凋亡的变化;western blotting分析p21、cyclin D1、Bcl-2、Bax蛋白的表达水平和ERK1/2通路的活化情况。结果:瘦素以剂量依赖性的方式促进人卵巢癌SKOV3细胞的增殖,同时抑制血清饥饿诱导的细胞凋亡。瘦素处理可下调p21和上调cyclin D1的表达,抑制促凋亡分子Bax的表达和上调抗凋亡分子Bcl-2的表达。瘦素可诱导细胞中ERK1/2通路的活化,其抑制剂PD98059可明显抑制瘦素诱导的促细胞增殖和抗凋亡作用,同时伴随有cyclin D1、Bcl-2蛋白表达的下调和Bax的上调。结论:瘦素可能通过活化ERK1/2通路调节细胞有丝分裂进程,进而促进卵巢癌细胞的增殖;同时通过调节凋亡相关蛋白Bcl-2和Bax的表达抑制卵巢癌细胞的凋亡。     

白细胞介素-1通过JNK信号通路调控Schlafen2基因的表达

目的：在多效生长因子（Ptn）基因稳定沉默的小鼠胚胎成纤维细胞Ptn-siRNA B/MEF241中,研究白细胞介素-1（IL-1）调控Schlafen2（Slfn2）基因表达的机制。方法：应用Northernblot检测Ptn沉默细胞Ptn-siRNAB/MEF241处于不同生长密度时Slfn2基因的表达变化,以确定Ptn沉默细胞中Slfn2基因的表达是否受到某种分泌性细胞因子的调控;用不同浓度的IL-1α中和抗体及IL-1受体拮抗剂处理Ptn沉默细胞,通过Northern blot检测细胞内Slfn2表达的抑制情况;用不同浓度的IL-1α中和抗体及IL-1受体拮抗剂处理Ptn沉默细胞不同时间,通过Western blot检测细胞中JNK磷酸化水平;Northern blot检测SP600125（JNK/MAPK通路抑制剂）对Ptn沉默细胞中Slfn2基因表达的影响。结果：Ptn沉默细胞中Slfn2基因的表达水平同细胞密度相关;用中和抗体和受体拮抗剂阻断IL-1通路,Slfn2表达受到显著抑制;IL-1受到抑制会影响JNK通路的活化;阻断JNK通路,Slfn2的表达受到显著抑制。结论：IL-1可以通过JNK通路诱导Slfn2的表达。     

雌激素对MAPK信号转导通路的作用机制

雌激素可以通过基因组作用和非基因组作用对细胞功能起调节作用。本文主要综述了其非基因组作用,即通过膜受体激活细胞内MAPK(ERK、p38、JNK)信号传导通路的过程。雌激素对ERK主要起促进作用,引起细胞增殖、分化以及血管扩张等生物学效应;对p38也起促进作用,而在不同的细胞中对JNK的作用不同,进而调节细胞凋亡、癌症发生等生命现象。     

E1A激活基因阻遏子过表达抑制体外人血管平滑肌细胞凋亡

为探讨E1A激活基因阻遏子（cellular repressor of E1A-stimulated genes,CREG）对人血管平滑肌细胞（vascular smooth muscl ecells,VSMCs）凋亡的影响及调控机制,应用正、反义重组逆转录病毒表达载体pLNCX,（＋）／CREG及pLXSN（-）／CREG制备稳定感染人胸廓内动脉平滑肌细胞克隆株（human internal thoracic artery-Shenyang,HITASY）细胞模型,观察CREG蛋白过表达及表达抑制对平滑肌细胞凋亡的影响。荧光显微镜下观察DAPI染色后凋亡细胞核形态,AnnexinV／PI流式细胞术检测细胞凋亡率,RT-PCR技术分析凋亡相关基因caspase-9mRNA的表达,蛋白质印迹法分析p38丝裂原活化蛋白激酶（p38 mitogen-activated protein kinase,p38MAPK）、磷酸化p38MAPK（phosphorylated p38 mitogen-activated proteinkinase,P-p38 MAPK）的表达变化。研究结果显示,CREG蛋白过表达明显抑制血清饥饿诱导的HITASY细胞凋亡的发生;同时细胞中p38MAPK、P-p38MAPK的表达增加。相反,抑制CREG蛋白表达则引起正常血清培养状态下VSMCs的自发凋亡明显增加,同时细胞内p38MAPK、P-p38MAPK表达显著下降。进一步研究发现,预先应用特异性抑制剂SB203580阻断p38MAPK信号转导通路后,CREG蛋白过表达引起的细胞凋亡抑制作用被明显减弱,血清饥饿后CREG蛋白过表达引起的HITASY细胞凋亡现象明显增加。上述结果提示,CREG蛋白过表达可以抑制体外培养的VSMCs凋亡,p38MAPK信号转导通路可能介导CREG蛋白对VSMCs凋亡的抑制作用。     

Effects of Pharmacological Concentrations of Estrogens on Growth of 3AO Human Ovarian Cancer Cells

During the past two decades, the knowledge of the molecular mechanism by which estrogens exert various functions in different tissues and organs has evolved rapidly. Recent reports demonstrated that estrogen could decrease the cell growth in several types of cancer cells, including ovarian cancer cells. Though experiments explored the possible mechanism of the inhibitory effect, the exact mechanism is responsible for the effect, which remains unclear. The ovary is the main source of the estrogen, estrogen receptor is expressed in several ovarian cell types, including ovarian surface epithelium, the tissue of origin of approximately 90% of the ovarian cancers. It was of great interest to analyze the effects of 17β-estradiol (E2) on apoptosis of ovarian cancer cells, and the identification of E2-regulated specific genes involved in epithelial proliferation apoptosis, thus may be a clue for understanding the progression of ovarian cancer and for the design of new target therapies. To elucidate the mechanism involved, effects of pharmacological concentrations of estrogen were studied in human ovarian cancer cell line 3AO cells. Inhibition of cellular growth of 3AO cells was seen with E2 at concentrations higher than 0.1 μmol/L. The estrogen receptor inhibitor ICI 182780 cannot block the inhibitory effect of E2. It was surprising to find that ICI 182780 itself can inhibit the growth of 3AO cells, and had a collaborative effect with E2. The decreased cell growth induced by E2 was shown to be apoptosis as analyzed by flow cytometry. ERβ was detected in the 3AO ovarian cancer cell line but not ERα. The expression of ERβ was weak, which may partially explain why high but not low dose of E2 needed to induce the apoptosis of 3AO cells. We also observed that membrane impermeable E2, E2-BSA have lost growth inhibitory on 3AO cells, which excluded the membrane effect of E2 as previously reported by many investigators. The p38 kinase inhibitor, SB203580 were partially protected 3AO cells against growth inhibition by E2, while inhibitor of JNK, SP600125 enhanced cell death induced by E2. These results showed that MAPK is implicated in cellular processes involving apoptosis.     

Wogonin inhibits IGF-1-stimulated cell growth and estrogen receptor α expression in breast adenocarcinoma cell and angiogenesis of chick chorioallantoic membrane

The aim of the present study was to investigate the involvements of insulin-like growth factor-1 (IGF-1) and estrogen receptor α (ERα) in the inhibitory effect of wogonin on the breast adenocarcinoma growth. Moreover, the effect of wogonin on the angiogenesis of chick chorioallantoic membrane (CAM) was also investigated. MCF-7 cells (human breast adenocarcinoma cell line) were subjected to several drugs, including IGF-1, wogonin and ER inhibitor ICI182780, alone or in combination. MTT assay was used to detect breast cancer proliferation. Western blot was used to analyze ERα and p-Akt expression levels. CAM models prepared from 6-day chicken eggs were employed to evaluate angiogenesis inhibition. The results showed wogonin and ICI182780 both exhibited a potent ability to blunt IGF-1-stimulated MCF-7 cell growth. Either of wogonin and ICI182780 significantly inhibited ERα and p-Akt expressions in IGF-1-treated cells. The inhibitory effect of wogonin showed no difference from that of ICI182780 on IGF-1-stimulated expressions of ERα and p-Akt. Meanwhile, wogonin at different concentrations showed significant inhibitory effect on CAM angiogenesis. These results suggest the inhibitory effect of wogonin on breast adenocarcinoma growth via inhibiting IGF-1-mediated PI3K-Akt pathway and regulating ERα expression. Furthermore, wogonin has a strong anti-angiogenic effect on CAM model.     

Effects of the environmental estrogens bisphenol A, o,p'-DDT, p-tert-octylphenol and coumestrol on apoptosis induction, cell proliferation and the expression of estrogen sensitive molecular parameters in the human breast cancer cell line MCF-7

In the presented study, we have analysed effects of the environmental estrogens bisphenol A (BPA), p-tert-octylphenol (OCT), o,p'-DDT (DDT) and coumestrol (COU) on cell proliferation, apoptosis induction, progesterone receptor (PR) and androgen receptor (AR) mRNA expression and ER alpha protein expression in comparison to estradiol (E2) and the selective ER modulator (SERM) raloxifene (RAL) and the pure antiestrogen faslodex (ICI 182780) in the human breast cancer cell line MCF-7. A dose dependent analysis of the cell cycle distribution of MCF-7 cells after administration of OCT, DDT and COU revealed a significant induction of cell proliferation and reduced rate of apoptosis. Maximum induction of cell proliferation and the lowest rate of apoptosis could be observed at a dose of 10(-6)M. Interestingly, administration of BPA reduces the rate of apoptosis, but does not enhance proliferation at any dose analysed. PR mRNA expression in MCF-7 cells was up regulated after administration of COU and DDT, whereas treatment with BPA and OCT did not effect PR mRNA expression. AR mRNA expression was down regulated by COU, but not effected by BPA, DDT and OCT. The expression of ER alpha protein in the breast cancer cells was slightly down regulated by COU and DDT, but unaffected by BPA and OCT. In summary and in comparison to the effects observed after administration of E2, RAL and ICI our data indicate that none of the analysed compounds exhibit properties comparable to RAL and ICI. COU and DDT exhibit properties which are very similar to E2. Administration of BPA and OCT did not effect any of the estrogen sensitive molecular parameters analysed. Nevertheless OCT is a very potent stimulator of cell proliferation in MCF-7 cells. Surprisingly, BPA is not able to induce the proliferation of MCF-7 breast cancer cells, but turns out to be a very potent inhibitor of apoptosis. For this reason and in agreement to the effects of BPA on the molecular parameters analysed, we conclude that BPA does not act in a classical estrogen like manner in MCF-7 breast cancer cells.     

The direct effect of estrogen on cell viability and apoptosis in human gastric cancer cells

Epidemiology researches indicated that gastric cancer is a male-predominant disease; both expression level of estrogen and expression pattern of estrogen receptors (ERs) influence its carcinogenesis. But the direct effect of estrogen on gastric cancer cells is still unclear. This study aimed to explore the direct effect of β-estradiol (E2) on gastric cancer cells. SGC7901 and BGC823 were treated with a serial of concentrations of E2. The survival rates of both the cell lines were significantly reduced, and the reduction of viability was due to apoptosis triggered by E2 treatment. Caspase 3 was activated in response to the increasing E2 concentration in both SGC7901 and BGC823. Cleaved Caspase 3 fragments were detected, and the expression levels of Bcl-2 and Bcl-xL were reduced. Apoptosis was further confirmed by flow cytometry. The expression level of PEG10, an androgen receptor target gene, was reduced during E2 treatment. Both ERα and ERβ were expressed in these cell lines, and the result of bioinformatics analysis of gastric cancer from GEO datasets indicated that the expression levels of both ERα and ERβ were significantly higher in noncancerous gastric tissues than in gastric cancer tissues. Our research indicated that estrogen can reduce cell viability and promote apoptosis in gastric cancer cells directly; ERs expression level is associated with gastric cancer. Our research will help to understand the mechanism of gender disparity in gastric cancer.     

17 beta-estradiol activates PI3K/Akt signaling pathway by estrogen receptor (ER)-dependent and ER-independent mechanisms in endometrial cancer cells

Cellular response to estrogen is mediated both by estrogen receptor (ER) binding to estrogen response element (ERE) and by non-nuclear actions like activation of signal transducing pathways. The main aims are to study if PI3K/Akt signaling pathway can be activated by 17beta-estradiol (E2) via non-nuclear action and to investigate the relationship of the action of E2 and ER in endometrial cancer cells expressing with different status of ER. The levels of phosphorylated Akt (Ser473) (P-Akt) and total Akt were examined by western blot and Akt kinase activity was measured in cells after stimulation with 1 microM E2 at different time points. Inhibitory role of LY294002 on activation of Akt induced by E2 and its estrogen antagonist, ICI182780 were also tested. P-Akt/Akt was used as a measure of activation of Akt. We found that maximum P-Akt/Akt and Akt kinase activity took place at 30 min in Ishikawa cells and 15 min in HEC-1A cells and the activation persisted for at least 2 h after stimulation with 1 microM E2. The activation of Akt elicited gradually with increasing doses of E2. PI3K inhibitor, LY294002, stopped the activating Akt in a dose-dependent manner and 50 microM LY294002 completely blocked the activation of Akt induced by E2. ICI182780 could block the activation of PI3K/Akt in ER-positive Ishikawa cells but not in HEC-1A cells with poor-expressed ER. This study demonstrated that E2 is able to promptly activate PI3K/Akt signal pathway in Ishikawa cells in an ER-dependent manner and ER-independent in HEC-1A cells. Blockage of PI3K/Akt cascade may become a potential and effective way to control endometrial carcinoma, especially in ER-negative cancers, which show no response to endocrinal therapy.     

Icaritin induces growth inhibition and apoptosis of human prostatic smooth muscle cells in an estrogen receptor-independent manner

Icaritin has selective estrogen receptor (ER) modulating activity. ERs are expressed in the prostate stroma, and estrogens have an important role in the pathology of benign prostatic hyperplasia (BPH). However, the impact of icaritin on BPH was not studied. Human prostatic smooth muscle cells (PSMCs) were treated with 0–100 μM icaritin, also using 10 μM ICI182780 as a specific ER antagonist. The effects on cell growth and apoptosis were determined by cell counting and sandwich-enzyme-immunoassay. Western blotting was employed to illustrate the possible mechanisms. Cell growth was strongly inhibited by icaritin, and this was accompanied by an augmented apoptosis. Few changes in icaritin-induced growth inhibition and apoptosis were observed after pretreatment in the presence of ICI182780. Consistent with growth inhibition and apoptosis induction, icaritin decreased cyclin D1 and CDK4 expression and increased Bax/Bcl-2 ratio in human PSMCs. Furthermore, icaritin induced sustained phosphorylation of extracellular signal-regulated kinase (ERK) in human PSMCs. PD98059, a specific ERK inhibitor, blocked the activation of ERK by icaritin and abolished the icaritin-induced growth inhibition and apoptosis. The results indicate that icaritin reduces growth and induces apoptosis in human PSMCs via ERK signaling pathway without involvement of ERs.     

Anti-proliferative effects of a novel isoflavone derivative in medullary thyroid carcinoma: An in vitro study

Currently available treatments for patients with medullary thyroid carcinoma (MTC) with residual or recurrent disease after primary surgery have low efficacy rates. In view of the possible role of estrogen in the development of thyroid neoplasia, we explored whether proliferation of the human MTC TT cell line, might be curbed by carboxy-daidzein-tBoc (cD-tBoc), a novel isoflavone derivative. Estrogen receptor (ER) α mRNA expression in TT cells was more abundant than ERβ, with a ratio of 48:1. Estradiol-17β (E2) increased DNA synthesis in a dose dependent manner. [(3)H]-thymidine incorporation was also stimulated by the ERβ agonist DPN and the ERα agonist PPT. cD-tBoc inhibited TT cell growth as assessed by thymidine incorporation, XTT assay, and microscopic analysis of culture wells. Creatine kinase specific activity, a marker of the modulatory effects of estrogen on cell energy metabolism, was likewise inhibited. The inhibitory effect of cD-tBoc on [(3)H]-thymidine incorporation could be blocked by the ERβ antagonist PTHPP but not by the ERα antagonist MPP, suggesting that the antiproliferative effect of cD-tBoc on these cells is mediated through ERβ. Furthermore, cD-tBoc potently increased apoptosis and cell necrosis. Co-incubation with the antiapoptotic agent Z-VAD-FMK reversed the growth inhibitory effect elicited by cD-tBoc. These results support the hypothesis that estrogens are involved in the proliferation of MTC. The potent anti-proliferative effects mediated by isoflavone derivatives in the human MTC cell line TT suggest and that this property may be utilized to design effective anti-neoplastic agents.     

Acteoside and martynoside exhibit estrogenic/antiestrogenic properties

Acteoside and martynoside are plant phenylpropanoid glycosides exhibiting anticancer, cytotoxic and antimetastatic activities. We investigated their potential to activate estrogen receptor isoforms ERalpha and ERbeta in HeLa cells transfected with an estrogen response element (ERE)-driven luciferase (Luc) reporter gene and an ERalpha or ERbeta expression vector. Their estrogenic/antiestrogenic effects were also assessed in breast cancer cells (MCF7), endometrial cancer cells (Ishikawa) and osteoblasts (KS483), by measuring IGFBP3 levels, cell viability and number of mineralized nodules, respectively, seeking for a natural selective estrogen receptor modulator (SERM). Acteoside and martynoside antagonized both ERalpha and ERbeta (p<0.001), whereas they reversed the effect of E(2) mainly via ERalpha (p<0.001). Martynoside was a potent antiestrogen in MCF-7 cells, increasing, like ICI182780, IGFBP3 levels via the ER-pathway. In osteoblasts, martynoside induced nodule mineralization, which was abolished by ICI182780, implicating an ER-mediated mechanism. Furthermore, its antiproliferative effect on endometrial cells suggests that martynoside may be an important natural SERM. Acteoside was an antiestrogen in breast cancer cells and osteoblasts, without any effect on endometrial cells. Our study suggests that the nature is rich in selective ERalpha and ERbeta ligands, the discovery of which may lead to the development of novel neutraceutical agents.     

Anti-thyroid cancer properties of a novel isoflavone derivative, 7-(O)-carboxymethyl daidzein conjugated to N-t-Boc-hexylenediamine in vitro and in vivo

The incidence of thyroid cancer is up to 3 folds higher in women than in men, suggesting that estrogenic effects may be involved in the pathogenesis of this malignancy. Here, we explore whether or not human thyroid cancer cell growth can be curbed by a novel isoflavone derivative generated in our laboratory, the N-t-Boc-hexylenediamine derivative of 7-(O)-carboxymethyl daidzein (cD-tboc). With the exception of the follicular cancer cell line WRO, estrogen receptor (ER)α mRNA was only marginally expressed in cell lines derived from papillary (NPA), follicular (MRO), anaplastic thyroid carcinoma (ARO) such that the expression of estrogen receptor (ER) βmRNA was more abundant than that of ERα mRNA in these cell types. Estradiol-17β (E2; 0.03-300nmol/l) per se increased proliferation in all four cell-types. The ERβ-specific agonist DPN increased [(3)H]-thymidine incorporation in all four thyroid cancer cell lines, whereas the ERα-specific agonist PPT increased growth only in NPA and WRO. By contrast, cD-tboc, derived from the weak estrogen daidzein, did not cause cell growth and dose-dependently diminished cell growth in all four cell lines via apoptosis and not necrosis, as detected by the release of histone-DNA fragments. The cytotoxic growth inhibitory effect of cD-tboc in these cells was modulated by E2 and the general caspase inhibitor Z-VAD-FMK, and the magnitude of this salvage was cell type-and dose-dependent. When nude mice carrying ARO thyroid xenografts were treated with cD-tboc, tumor volume decreased significantly, and no apparent toxicity was observed. These results suggest that cD-tboc may be a promising agent for therapy of thyroid carcinoma either alone or in combination with existing cytotoxic drugs.